Scynexis (SCYX) Tops Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 7:00 AM EDTBREXAFEMME® (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMMEs labelling to include the prevention of recurrent vulvovaginal candidiasis (RVVC); the FDA assigned a target PDUFA action date of November 30, 2022 for this additional indication.Enrollment has begun in two Phase 3 trials: the MARIO study is evaluating ibrexafungerp as an oral... More
